Therapeutic siRNA for drug-resistant HER2-positive breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Nanotechnology

Background:

• HER2 overexpression in breast cancer correlates with poor prognosis and resistance to HER2-targeted therapies such as trastuzumab.
• Acquired or intrinsic resistance to HER2-targeted drugs necessitates alternative therapeutic strategies for HER2-positive cancers.
• A specific HER2 splice variant (exon 16 skipped) is oncogenic and associated with trastuzumab resistance.

Purpose of the Study:

• To identify an optimal HER2-targeting small interfering RNA (siRNA) sequence.
• To evaluate the efficacy of the identified HER2 siRNA in overcoming resistance to HER2-targeted therapies.
• To assess the potential of HER2 siRNA delivered via nanoparticles for treating resistant HER2-positive breast cancer.

Main Methods:

• Systematic screening of 76 HER2 siRNA sequences to identify the optimal candidate.
• In vitro testing of HER2 siRNA efficacy across 18 HER2-positive cancer cell lines, including those with primary or acquired resistance to trastuzumab and lapatinib.
• In vivo studies using a nanoparticle delivery system to administer HER2 siRNA to trastuzumab-resistant tumors in a preclinical model.
• Analysis of HER2 splice variant silencing by the optimal HER2 siRNA.

Main Results:

• An optimal HER2 siRNA sequence was identified from 76 candidates.
• The selected HER2 siRNA demonstrated efficacy in overcoming both intrinsic and acquired resistance to trastuzumab and lapatinib in multiple HER2-positive cancer cell lines.
• Drug-resistant cancer cells remained dependent on HER2 for survival, and resistance to HER2 siRNA did not readily develop upon extended treatment.
• Systemic delivery of HER2 siRNA via nanoparticles significantly inhibited the growth of trastuzumab-resistant tumors.
• The optimal HER2 siRNA successfully silenced the oncogenic exon 16 skipped HER2 splice variant.

Conclusions:

• The identified HER2 siRNA is a potent agent for overcoming resistance to current HER2-targeted therapies in breast cancer.
• HER2 remains a critical survival factor in drug-resistant HER2-positive cancers, making it a viable target for siRNA-based therapies.
• Nanoparticle-mediated systemic delivery of HER2 siRNA offers a promising strategy for treating resistant HER2-positive breast cancer.
• The optimal HER2 siRNA has the potential to target both wild-type HER2 and the resistant splice variant, offering broader therapeutic application.